StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) company profile

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

About Candel Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Candel Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf viral immunotherapies designed to stimulate systemic immune responses against cancer. Its investigational pipeline features two primary clinical candidates: aglatimagene besadenovec, an adenovirus-based therapy evaluated for localized prostate cancer, non-small cell lung cancer, and pancreatic cancer, and linoserpaturev, a herpes simplex virus construct being evaluated for recurrent high-grade glioma. The company also engineers early-stage solid tumor candidates using its enLIGHTEN discovery platform. Its target patients include individuals with solid tumors, especially those showing limited responses to standard oncology treatments.

Operationally, the company conducts multi-center clinical studies in the United States and Mexico. It retains development and commercialization rights across major territories, including the United States, Europe, and Asia, while utilizing third-party contract manufacturers for production. The business is incorporated in Delaware; its specific headquarters location is not stated in the text.

Summary of the business section of Candel Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Candel Therapeutics, Inc.
Founded
2003
Headquarters
Needham, MA
Address
117 Kendrick Street, Suite 450 02494
Phone
(617) 916-5445
Employees
55, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Boston, Massachusetts

Stock & identifiers

Ticker
CADL
Exchange
Nasdaq
IPO date
Jul 28, 2021
Shares outstanding
77M, Aug 6, 2026
Public float
$245.30M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1841387
CUSIP
137404109
ISIN
US1374041093
FIGI
BBG00N0D4Z71
Share class FIGI
BBG00N0D4Z80
EIN
52-2214851

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Paul Peter TakChief Executive Officer, Director113,321
Maria OstrovskyGeneral Counsel–
Seshu TyagarajanChief Technology Officer76,865
Mark E. SimsChief Commercial Officer–
Francesca BaroneChief Scientific Officer77,362
Charles SchochChief Financial Officer43,391
William Garrett NicholsChief Medical Officer52,493
Paul B. ManningDirector5,748,279
Nicoletta LoggiaDirector2,141
Joseph C. PapaDirector102,271
Martine ZimmermannDirector–
Renee GaetaDirector–
Christopher MartellDirector698,863
Maha RadhakrishnanDirector–
Gary J. NabelDirector5,353
Diem NguyenDirector10,000
Edward J. Benz JRDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Paul Peter Tak, M.D., Ph.D., FMedSci
Chief Executive Officer
$743.59K$3.92M$396.65K$288.29K$5.34M+269%
Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
$483.31K$857.80K$206.43K$14.00K$1.56M+115%
Charles Schoch
Chief Financial Officer
$398.50K$826.47K$232.32K$13.53K$1.47M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 28, 2021
Offer price
$8.00
Securities offered
9,000,000
Gross proceeds
$72.00M
Exchange
Nasdaq
First trading day
Jul 27, 2021
First-day close
$7.00-12.5%
Lock-up ends (est.)
Jan 23, 2022

“The initial public offering price is $8.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 55 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?